{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:58:24Z","timestamp":1783465104178,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection represents a major global public health issue, affecting hundreds of millions worldwide and serving as a primary cause of cirrhosis and hepatocellular carcinoma. In recent years, immunotherapies aimed at reconstituting or enhancing the host immune response to control or even clear HBV have emerged as one of the most promising strategies for achieving functional cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of the Web of Science Core Collection (WoSCC) and Scopus databases identified 3,029 relevant articles published between January 2005 and December 2025. Using VOSviewer, CiteSpace, and Scimago Graphica as bibliometric tools, evaluation metrics were extracted or calculated to analyze and visualize the knowledge map. Publications were categorized by country, institution, author, journal, highly cited papers, and keywords. These variables were compared in terms of publication output and academic influence, including metrics such as citation counts, citation impact, H-index, and journal impact factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,029 relevant publications were retrieved, originating from 116 countries or regions and 4188 research institutions. China and the United States led in both publication volume and impact; the most prolific institution was the Institut national de la sant\u00e9 et de la recherche m\u00e9dicale, followed by the University of London. Frontiers in Immunology was the most frequently cited journal; Janssen, Harry L A was the most prolific author, while Zoulim, Fabien had the highest H-index among all authors. Keyword clustering identified four primary categories: \u201cfunctional cure\u201d, \u201chepatocellular carcinoma\u201d, \u201ccase report\u201d and \u201cadvanced hepatocellular carcinoma\u201d. Keyword and citation trends indicated three major research hotspots: persistent viral reservoirs, profound immune system depletion, and progression-driven mechanisms in hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This bibliometric analysis indicates that research on hepatitis B immunotherapy has experienced rapid development over the past two decades and is projected to grow rapidly toward the goal of \u201cfunctional cure\u201d in the coming years. Literature trends suggest that combination therapy strategies involving drugs with different mechanisms of action have been increasingly investigated for achieving functional cure for hepatitis B. Furthermore, comparative analysis of research trends across various immunomodulatory treatment regimens will contribute to a more comprehensive understanding of investigational therapeutic pathways in the near future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1775211","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:07:48Z","timestamp":1780466868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A bibliometric analysis of immunotherapy for chronic hepatitis B: trends and hotspots prediction"],"prefix":"10.3389","volume":"17","author":[{"given":"Xingtao","family":"Jin","sequence":"first","affiliation":[{"name":"Institute of Cellular Immunity Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Institute of Shanghai Key Laboratory of Traditional Chinese Clinical Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Cellular Immunity Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Institute of Shanghai Key Laboratory of Traditional Chinese Clinical Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlu","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute of Cellular Immunity Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]},{"name":"Institute of Shanghai Key Laboratory of Traditional Chinese Clinical Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Shanghai Key Laboratory of Traditional Chinese Clinical Medicine","place":["Shanghai, China"]},{"name":"Institute of Infectious Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqiu","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Shanghai Key Laboratory of Traditional Chinese Clinical Medicine","place":["Shanghai, China"]},{"name":"Institute of Infectious Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.995857","article-title":"Assessment and validation of the TREAT-B score to assess the treatment eligibility of patients with chronic hepatitis B virus infection","volume":"9","author":"Thanapirom","year":"2022","journal-title":"Front Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet (London England)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i6.725","article-title":"Clinical utility of hepatitis B surface antigen kinetics in treatment-na\u00efve chronic hepatitis B patients during long-term entecavir therapy","volume":"24","author":"Lin","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13291","article-title":"Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)","author":"Grossi","year":"2017","journal-title":"Liver Intl: Off J Int Assoc For Study Liver"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.06.004","article-title":"Current treatments for chronic hepatitis B virus infections","volume":"18","author":"Zoulim","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2050640614525151","article-title":"Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients","volume":"2","author":"Lesmana","year":"2014","journal-title":"United Eur Gastroenterol J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.052","article-title":"Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B","volume":"138","author":"Fisicaro","year":"2010","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112754","article-title":"HBV immune-therapy: From molecular mechanisms to clinical applications","volume":"20","author":"Boni","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2198209","article-title":"The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review","volume":"19","author":"Allahmoradi","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020216","article-title":"Targeting host innate and adaptive immunity to achieve the functional cure of chronic hepatitis B","volume":"8","author":"Ezzikouri","year":"2020","journal-title":"Vaccines"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1033683","article-title":"Global publication trends and research hotspots of curcumin application in tumor: A 20-year bibliometric approach","volume":"12","author":"Habu","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1752-8","article-title":"Complement factors C3a and C5a mimic a proinflammatory microenvironment and increase HBV IGRA sensitivity","volume":"17","author":"Br\u00f6ker","year":"2019","journal-title":"J Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12749","article-title":"HBV and the immune response","author":"Ferrari","year":"2015","journal-title":"Liver Intl: Off J Int Assoc For Study Liver"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314098","article-title":"Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection","volume":"67","author":"Song","year":"2018","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051210","article-title":"A systematic review of the advances in the study of T lymphocyte suppressor receptors in HBV infection: Potential therapeutic targets","volume":"13","author":"Zhou","year":"2024","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29239","article-title":"Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice","volume":"66","author":"Sun","year":"2017","journal-title":"Hepatol (Baltimore Md)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.62424","article-title":"CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV","volume":"18","author":"Zhao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr Opin Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:07:48Z","timestamp":1780466868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1775211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1775211"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1775211","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1775211"}}